Pfizer wins at CAFC in Neurontin/gabapentin matter
In another chapter in the Neurontin (gabapentin) story, Reuters reported on Sept. 21:
Pfizer Inc said a federal appeals court [CAFC] overturned a lower court ruling [D NJ] that several generic-drug makers did not infringe its patent on gabapentin, the active ingredient in Neurontin, a shingles-pain treatment.
Pfizer said the ruling will allow it to seek a judgment of infringement and, if successful, pursue full compensation for the damage it suffered from the 2004 launch of generic versions of Neurontin.
IPBiz notes that the story was reported by Supantha Mukherjee and Neha Pathania in Bangalore.
Pfizer Inc said a federal appeals court [CAFC] overturned a lower court ruling [D NJ] that several generic-drug makers did not infringe its patent on gabapentin, the active ingredient in Neurontin, a shingles-pain treatment.
Pfizer said the ruling will allow it to seek a judgment of infringement and, if successful, pursue full compensation for the damage it suffered from the 2004 launch of generic versions of Neurontin.
IPBiz notes that the story was reported by Supantha Mukherjee and Neha Pathania in Bangalore.
posted by Lawrence B. Ebert at 8:11 AM
0 Comments:
Post a Comment
<< Home